Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;37(4):1319-1327.
doi: 10.1007/s12325-020-01261-w. Epub 2020 Feb 21.

Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview

Affiliations
Review

Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview

Andreas Katsanos et al. Adv Ther. 2020 Apr.

Abstract

Emerging evidence has suggested that the entoptic phenomena associated with vitreous opacities (i.e. vitreous floaters) are more bothersome than previously believed. In addition, the prevalence of vitreous floaters is likely increasing due to the evolving global pandemic of myopia. The use of YAG laser vitreolysis for the treatment of annoying vitreous floaters has attracted significant attention in recent years as the technique offers a number of potential advantages. Unfortunately, the currently available evidence that is needed to guide clinical practice is both very limited and contradictory. As a consequence, the technique remains highly controversial. A review of the existing literature sheds light on patient- and treatment-related factors that may significantly affect both the effectiveness and the safety of the procedure. The current article discusses important aspects of key publications on the topic, offers suggestions for clinical practice, and highlights unmet needs that should be addressed by future research.

Keywords: Floaters; Myodesopsia; Ophthalmology; PVD; Posterior vitreous detachment; Vitreolysis; Vitreous floaters; Weiss ring; YAG.

PubMed Disclaimer

References

    1. Webb BF, Webb JR, Schroeder MC, North CS. Prevalence of vitreous floaters in a community sample of smartphone users. Int J Ophthalmol. 2013;6:402–405. - PMC - PubMed
    1. Wagle AM, Lim W-Y, Yap T-P, Neelam K, Au Eong K-G. Utility values associated with vitreous floaters. Am J Ophthalmol. 2011;152(60):65.e1. - PubMed
    1. Zou H, Liu H, Xu X, Zhang X. The impact of persistent visually disabling vitreous floaters on health status utility values. Qual Life Res. 2013;22:1507–1514. - PubMed
    1. Kim Y-K, Moon SY, Yim KM, Seong SJ, Hwang JY, Park SP. Psychological distress in patients with symptomatic vitreous floaters. J Ophthalmol. 2017;2017:3191576. - PMC - PubMed
    1. Sendrowski DP, Bronstein MA. Current treatment for vitreous floaters. Optometry. 2010;81:157–161. - PubMed